Introduction
Neuroblastoma is one of the most common malignant diseases of early childhood. Depending on the individual risk profile of the patient the disease can either regress with minimal or even no treatment or can lead to death despite intensive multimodality high-risk treatment. Therefore neuroblastoma has been a model for risk adapted therapy for many years. The combination of multiple clinical and molecular variables increasingly allows adapting the treatment according to the individual needs of the patient. Individualized treatment aims to avoid inefficient treatments in refractory disease, to identify patients who benefit from alternative experimental treatments, and to de-escalate treatment in low risk patients. General strategies for treatment individualization in cancer treatment are (1) risk adapted treatment by precise pre-treatment risk prediction based on clinical and/or molecular characteristics, (2) structured treatment modifications based on the response to treatment, (3) and molecular targeted therapies based on individual molecular characteristic of the tumor (Table 1) . It is important to note, that individualized treatment must follow structured guidelines which are either subject to prospective clinical trials or have already been evaluated by prospective clinical trials. Individualized therapy solely based on individual believes of physicians are very likely to impair the outcome of patients. 
Molecular risk prediction
The majority of low and intermediate risk patients will achieve stable first remission with limited treatment [26] [27] [28] . Moreover, most of relapses or progressions are cured with moderate second-line treatment. However, some patients experience sequential relapses or progressions and finally succumb of disease. It is challenge to identify those risk patients early at initial diagnosis in order to apply the adequate first-line therapy. Retrospective studies indicate that molecular analyses of copy number aberrations by array CGH [29] and RNA expression analysis by microarray [18, 30] may allow the identification of these risk patients: In infants, the presence of segmental chromosomal aberrations in the tumor was associated with inferior outcome (5 year EFS 70.7% ± 6.6%) compared to children whose tumors lacked segmental chromosomal aberrations (5-year EFS 92.0% ± 2.1%). This impact of segmental chromosomal aberrations was even stronger in the subgroup of stage 4S patients who had not undergone frontline chemotherapy (5 year EFS 25.0% ± 15.3% vs. 95.3% ± 3.2%) [29] . Another approach is based on a gene expression signature which has been developed by the analysis of the RNA expression profiles in neuroblastomas obtained from patients with favorable outcome and unfavorable outcome. The gene expression classifier identified risk patients better than established risk groups definitions: Among patients classified as low risk by stage, age, and MYCN, the classifier identified a small group of risk patients with poor outcome (5 year
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О р и г и н а л ь н ы е и с с л е д о в а н и я / О б з о р ы л и т е р а т у р ы EFS 29% ± 10% vs. , 84% ± 2%, 5 year OS 76% ± 11% vs. 99% ± 1%). Similar results were found among patients classified as intermediate risk (5 year EFS 41% ± 10% vs. 88% ± 6%, 5 year OS 70% ± 9% vs. 100%) and high risk (5 year EFS 33% ± 3% vs. 63% ± 9%, 5 year OS 46±4% vs. 83±7%) [30] . Prospective clinical trials are open or will be open soon in order to assess whether the precise identification of risk patients based on molecular findings will improve the outcome. In these trials, treatment may be either intensified for patients with unfavorable risk profile or reduced for patients with favorable characteristics.
Treatment individualization based on response to treatment Low-and intermediate-risk neuroblastoma
Spontaneous regression of infant neuroblastoma is a well described phenomenon [27, [31] [32] [33] [34] . Over-diagnosis of localized neuroblastoma found by screening programs also indicates a substantial number of spontaneous regressions during and after the 1st year of life [35] . In low risk neuroblastoma patients, individualization of treatment first of all aims to de-escalate chemotherapy and to limit operations in patients with favorable risk profile. It also aims to identify those few patients in the low risk group who are at risk for tumor progression finally leading to death despite multiple sequential treatments. The German NB95-S trial demonstrated a high rate of spontaneous regressions in patients <1 year of age at diagnosis with localized neuroblastoma. Some infants required chemotherapy in order to overcome symptomatic transient tumor progression [27] . It has been demonstrated in the trial that limited intensity chemotherapy can induce regression in low risk neuroblastoma. This approach has been further developed and is currently being tested in the NB2004 trial including an extended cohort of low risk neuroblastoma patients (stage 1 neuroblastoma patients aged 0-21 years diagnosis, stage 2 neuroblastoma aged 0-21 years at diagnosis without aberration of chromosome 1p, stage 3 neuroblastoma patients 0-2 years of age without aberrations of chromosome 1p, and stage 4S patients 0-1 year of age at diagnosis). Patients with tumor associated threatening symptoms or rapid progression, who are otherwise classified as observation patients, are scheduled for chemotherapy with vincristine, cyclophosphamide and doxorubicin. According to the protocol, the chemotherapy is stopped as soon as the tumor induced symptoms are relieved and/or tumor progression is stopped. Results of the trial NB2004 are not published yet, but interim analysis demonstrated that the burden of chemotherapy was reduced without increase of event and death rate.
High-risk neuroblastoma
The situation is very different in high-risk neuroblastoma. With high-intensive multimodality treatments, about 50% of patients survive at least 5 years after diagnosis [36] . Long term survivors of high-risk neuroblastoma face several late effects such as hearing impairment [37] [38] [39] [40] , hypothyroidism [40, 41] , focal nodular hyperplasia of the liver [42] , pulmonary and cardiac diseases [43] , and second malignant disease [44] [45] [46] . Early response assessment aims to detect patients in whom conventional induction chemotherapy will most likely fail, and who therefore may require new experimental treatment strategies. Several approaches have been applied in order to identify these ultra-high risk patients: Studies on the prognostic value of residual bone marrow involvement using different techniques such as immuno-cytology and PCR analysis resulted in controversial results [47] [48] [49] . Prospective trials on the prognostic value of bone marrow clearance using standardized techniques are still ongoing, but final results are not available yet. Delayed clearance of MIBG positive lesions during induction chemotherapy was found predictive for poor outcome in retrospective analyses [50, 51] . The prognostic value of residual MIBG positive lesions during and after induction therapy has been further improved by the application of semi-quantitative scoring systems such as the Curie and the SIOPEN system [51] [52] [53] . In addition, response of the primary tumor was also found to be prognostic value on outcome in patients with stage 4 neuroblastoma as well as in patients with MYCN amplified neuroblastoma regardless of stage. However, only the reduction of the longest tumor diameter >30% but not the reduction of the tumor volume during induction chemotherapy was associated with better EFS and OS [54] .
Treatment individualization by molecular targeted therapies
Another promising innovative treatment approach is currently the application of designed compounds which interact with the target of the tumor cells. Serious systemic off-target side effects may be attenuated or even avoided when the molecular target is not expressed or not mutated in normal cells. Examples of several molecular targets in neuroblastoma are found in Table 2 . The ganglioside GD2 is the target for GD2-directed immunotherapy [55] [56] [57] [58] . It is expressed by most of primary neuroblastoma. Therefore, anti GD2 directed drugs are targeted but not strictly individualized therapies. Angiogenesis is also up-regulated in all high-risk neuroblastoma patients. Pre-clinical data on the effects of anti-angiogenetic treatment are conflicting [59, 60] while phase I clinical trials have given encouraging results [61, 62] . The norepinephrine transporter system is the molecular basis for MIBG therapy [63] [64] [65] [66] . High-dose MIBG therapy is commonly applied if MIBG positive lesions are present after induction chemotherapy and is, therefore, an example for response adapted individualized therapy particularly when applied during first-line therapy [65] . In addition, MIBG therapy has also been applied as frontline-therapy [66, 67] and in relapsed MIBG positive neuroblastoma [64, 68, 69] . Furthermore, the RAS/MAPK
О р и г и н а л ь н ы е и с с л е д о в а н и я / О б з о р ы л и т е р а т у р ы pathway seems to play an important role in malignant growth particularly in relapsed neuroblastoma [17, 70, 71] . Treatment with selected inhibitors of downstream targets of the pathway is considered a promising approach of targeted treatment [70, [72] [73] [74] [75] [76] [77] . However, clinical data on these treatments particularly in combination with chemotherapies with are very limited, so far [78, 79] .
The mutation frequency in neuroblastoma is low, and the spectrum of mutations is heterogeneous, resulting in a limited number of potential targets for individualized molecular therapies [80] . More recent studies suggest that the molecular hallmark of high-risk neuroblastoma is activation of telomere maintenance mechanisms, separating it from tumors that will eventually regress [81] . Telomere maintenance may be mediated by either telomerase induction, caused by rearrangements of the telomerase reverse transcriptase encoding gene TERT or by MYCN amplification, or by activation of the alternative lengthening of telomeres pathway, facilitated by inactivating ATRX mutations. In general, targeting aberrant molecular structures is considered as an ideal example of individualized treatment strategies, because such therapies are based on individual molecular characteristics of the tumor. Most of the molecular aberrations observed in neuroblastoma are not specific for this malignancy, such as induction of telomerase, which is present in the vast majority of cancers, or activating ALK mutations, which may also occur in lung cancer or lymphomas. Furthermore, most of the molecular targeted treatments are only effective if the aberrant target or target pathway is present in the tumor tissue of the individual patients. Tumor biopsy and tumor tissue banking are, therefore, are mandatory at first diagnosis and at relapse.
One of the most promising targets in neuroblastoma are activating mutations of the tyrosine receptor kinase ALK, which are found in about 10% of neuroblastoma patients [82, 83] . One phase I trial on the ALK inhibitor crizotinib in refractory pediatric solid tumors demonstrated acceptable toxicity and promising response. Among 11 neuroblastoma patients with known ALK mutations one complete remission and two stable diseases were observed [82, 84] . New ALK inhibitors, such as ceritinib and alectinib, are expected to be more effective on different types of ALK mutations [85] [86] [87] . Phase 3 trials on primary neuroblastoma with ALK mutations are currently in preparation and will assess the value of ALK inhibition as an element in high-intensive multimodality treatment protocols.
Amplification of the oncogene MYCN is found in about 20% of neuroblastoma. Effective inhibition of MYCN by BET bromodomain inhibitors has been demonstrated in vitro, but the compounds are not available for clinical trials, so far [88] . In an alternative approach, the MYCN pathway has been identified as a potential target for molecular therapies via inhibition of Aurora kinase A. Aurora kinase A plays a crucial role in stabilization and degradation of MYCN and, therefore, is considered as potential target [89, 90] . The Aurora kinase A inhibitor alisertib has recently successfully been tested as single agent [91] as well as in combination with irinotecan and temozolomide [92] .
Summary
Neuroblastoma is an ideal model tumor for establishing individualized therapies because of its divergent courses of the disease. Individualization of cancer therapies can either focus on precise initial risk prediction of the patients at the time of diagnosis as prerequisite for risk adapted treatment, on О р и г и н а л ь н ы е и с с л е д о в а н и я / О б з о р ы л и т е р а т у р ы Введение Нейробластома (НБ) является одной из наиболее частых злокачественных опухолей у детей раннего возраста. В зависимости от индивидуальных харак-теристик опухоли НБ может либо регрессировать по-сле минимальной полихимиотерапии или даже без лечения, либо приводить к смерти, несмотря на про-ведение комбинированной высокоинтенсивной тера-пии. Поэтому НБ на протяжении многих лет рассма-тривалась как модель для риск-адаптированной терапии. Комбинация определенных клинических и молекулярных данных позволяет адаптировать те-рапию в соответствии с индивидуальными потреб-ностями пациента. Индивидуализированное лечение направлено на то, чтобы избежать неэффективных методов при рефрактерном течении заболевания, вы-деляя группу пациентов для проведения альтерна-тивных экспериментальных методов лечения, а также для деэскалации терапии для пациентов группы низ-кого риска. Основная стратегия индивидуализиро-ванной терапии злокачественных новообразований основана на риск-адаптированном лечении [1] путем определения факторов риска до начала терапии, основанных на клинических и/или молекулярных характеристиках опухоли [2] , модификации терапии в зависимости от ответа на лечение [3] и молекуляр-ной таргетной терапии, основанной на индивидуаль-ных молекулярных характеристиках опухоли (табл. 1). Важно отметить, что индивидуализация терапия должна проводиться на основе четко структуирован-ных рекомендаций, которые являются или предме-том изучения в простпективных клинических иссле-
